Canaccord Genuity Raises Zeltiq Aesthetics Inc. (ZLTQ) Price Target to $45.00
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) had its price objective hoisted by Canaccord Genuity from $41.00 to $45.00 in a report issued on Thursday. Canaccord Genuity currently has a buy rating on the stock.
Other equities analysts have also issued research reports about the stock. Leerink Swann reiterated an outperform rating and set a $43.00 price objective on shares of Zeltiq Aesthetics in a report on Wednesday, July 13th. JPMorgan Chase & Co. reiterated a hold rating and set a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a report on Tuesday, August 9th. Brean Capital set a $39.00 price objective on shares of Zeltiq Aesthetics and gave the company a buy rating in a report on Tuesday, August 9th. Zacks Investment Research lowered shares of Zeltiq Aesthetics from a hold rating to a sell rating in a report on Thursday, July 14th. Finally, Stifel Nicolaus upped their price objective on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a buy rating in a report on Wednesday, September 21st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $42.78.
Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.63 on Thursday. The company’s 50-day moving average price is $37.66 and its 200-day moving average price is $33.50. Zeltiq Aesthetics has a 12-month low of $18.41 and a 12-month high of $41.48. The company has a market cap of $1.58 billion, a PE ratio of 51.14 and a beta of 0.89.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings results on Wednesday, November 9th. The company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.04. The business had revenue of $95.20 million for the quarter, compared to analysts’ expectations of $90.84 million. Zeltiq Aesthetics had a net margin of 9.48% and a negative return on equity of 6.45%. The business’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 earnings per share. Equities analysts anticipate that Zeltiq Aesthetics will post ($0.08) earnings per share for the current year.
In other news, insider Mark J. Foley sold 10,000 shares of the stock in a transaction that occurred on Thursday, October 13th. The shares were sold at an average price of $40.55, for a total transaction of $405,500.00. Following the completion of the transaction, the insider now directly owns 281,941 shares of the company’s stock, valued at approximately $11,432,707.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Sergio Garcia sold 20,000 shares of the stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $39.08, for a total transaction of $781,600.00. Following the transaction, the vice president now directly owns 86,241 shares of the company’s stock, valued at $3,370,298.28. The disclosure for this sale can be found here. Insiders own 15.60% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PineBridge Investments L.P. increased its position in Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock valued at $112,000 after buying an additional 193 shares during the period. BlackRock Inc. increased its position in Zeltiq Aesthetics by 11.3% in the third quarter. BlackRock Inc. now owns 3,265 shares of the company’s stock valued at $128,000 after buying an additional 332 shares during the period. Teacher Retirement System of Texas increased its position in Zeltiq Aesthetics by 26.9% in the second quarter. Teacher Retirement System of Texas now owns 4,884 shares of the company’s stock valued at $133,000 after buying an additional 1,036 shares during the period. Mason Street Advisors LLC acquired a new position in Zeltiq Aesthetics during the second quarter valued at approximately $173,000. Finally, Bank of Montreal Can increased its position in Zeltiq Aesthetics by 49.2% in the third quarter. Bank of Montreal Can now owns 4,794 shares of the company’s stock valued at $188,000 after buying an additional 1,580 shares during the period.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.